Arecor Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
May 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jul 14, 2027The maintenance fee for Stabilized aqueous antibody compositions (US 10,532,098) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 1 fee due Aug 9, 2027The maintenance fee for Stable aqueous formulations of adenovirus vectors (US 9,254,332) comes due Aug 9, 2027. Unpaid by Feb 9, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,486,388 | Protein formulation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,005,611 | Protein Formulation In force · Medium confidence | In force | Medium confidence | |
| US 9,023,985 | Glucagon composition In force · From the USPTO record | In force | From the USPTO record | |
| US 10,925,965 | Protein formulations with increased stability In force · From the USPTO record | In force | From the USPTO record | |
| US 12,016,922 | Stabilized aqueous antibody compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 9,254,332 | Stable aqueous formulations of adenovirus vectors In force · From the USPTO record | In force | From the USPTO record | |
| US 9,744,242 | Stable aqueous formulations of adenovirus vectors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,532,098 | Stabilized aqueous antibody compositions In force · From the USPTO record | In force | From the USPTO record | |
| US 11,278,624 | Formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 11,534,402 | Liquid pharmaceutical composition In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 16: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
8 pending · 3 abandoned · 27 no status recorded